SNWV — SANUWAVE Health, Inc.

Summary of SANUWAVE (SNWV) Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Q3 2025 revenue reached $11.5 million, a 22% increase year-over-year and a 13% increase sequentially from Q2. Year-to-date revenue growth for the first nine months of 2025 stands at 39%.
• Gross Margin: Gross margin was 77.9%, slightly down from 78.2% in Q2 but up from 75.5% a year ago.
• Operating Income: Operating income was $1.5 million, down from $2 million in Q3 2024, attributed to increased operating expenses.
• Net Income: Net income was $10.3 million compared to a net loss of $20.7 million in Q3 2024, primarily due to a noncash gain from derivative liabilities and a $5 million gain from a patent sale.
• EBITDA: EBITDA for the quarter was $12.4 million, with adjusted EBITDA at $3.5 million, up from $2.1 million in the previous year.
• Cash Position: Cash totaled $9.6 million as of September 30, 2025.

2. Strategic Updates and Business Highlights:

• Product Sales: Sold 155 UlTraMIST systems in Q3, marking a record high, with a total of 1,416 units in the field.
• Debt Refinancing: Successfully refinanced debt, reducing it from approximately $27.5 million to $24 million, and lowered the interest rate from 19.5% to SOFR + 350 basis points.
• Operational Improvements: The company is working on a new four-cavity mold for applicators expected to enhance production efficiency and margins by 2026.
• Market Dynamics: The wound care market is experiencing uncertainty due to changes in reimbursement policies, but SANUWAVE anticipates opportunities for growth as clarity emerges.

3. Forward Guidance and Outlook:

• Q4 Revenue Guidance: SANUWAVE projects Q4 2025 revenues between $13 million and $14 million, representing a year-over-year increase of 26% to 36%.
• Market Adaptation: The company expects a rapid adaptation to new reimbursement realities, which could lead to increased sales and market engagement.

4. Bad News, Challenges, or Points of Concern:

• Market Uncertainty: The wound care market is unsettled due to changes in reimbursement for skin substitutes, leading to a cautious approach from practitioners.
• Increased Operating Expenses: Operating expenses rose significantly, driven by stock-based compensation and increased headcount, which could pressure future profitability.
• Sales Channel Management: Balancing direct sales and reseller channels remains a challenge, particularly in avoiding conflicts and managing inventory effectively.

5. Notable Q&A Insights:

• Reseller Interest: There is heightened interest from resellers of skin substitutes looking to diversify their offerings, presenting potential opportunities for SANUWAVE.
• Sales Strategy: The company is exploring ways to effectively integrate distributor and direct sales efforts while managing inventory risks.
• International Opportunities: While currently focused on domestic markets, SANUWAVE is open to exploring international distribution partnerships if compelling opportunities arise.
• Capital Approval Processes: The company is considering rental models for hospitals to navigate capital approval challenges, which could facilitate broader adoption of UltraMIST systems.

Overall, SANUWAVE reported a strong quarter with record revenues and a positive outlook, despite facing challenges in the wound care market and rising operational costs. The company is strategically positioned to leverage market changes and improve its sales channels.